Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients

Jung Sun Kim, Tae Soo Kang, Jin Bae Kim, Hye Sun Seo, Sungha Park, Changsoo Kim, Young Guk Ko, Donghoon Choi, Yangsoo Jang, Namsik Chung

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

C-reactive protein (CRP) has been known to be associated with vascular inflammation and hypertension. Pulse wave velocity (PWV) increases according to the degree of the arterial stiffness in hypertension patients. Therefore, PWV may be correlated with CRP levels in treated hypertensive patients, irrespective of medication. We sought to determine whether there is a correlation between hsCRP and arterial stiffness in non-diabetic treated hypertensive patients, independent of cardiovascular risk factor. This study consisted of 424 non-diabetic patients at least 45-years-old who were being treated for hypertension. At the time of enrollment, the patients underwent a baseline laboratory assessment of C-reactive protein levels and pulse wave velocity (PWV). Heart to femoral PWV (hfPWV) and brachial to ankle PWV (baPWV) were used as a marker of arterial stiffness. Subjects were categorized according to tertiles of hsCRP level [Group 1: first tertile (0.20-0.46 mg/L), Group 2: second tertile (0.47-1.15 mg/L), Group 3: third tertile (1.17-9.71 mg/L)]. Group 1 consisted of 141 patients (mean age 58 ± 8 years), Group 2 had 142 patients (mean age 60 ± 9 years) and Group 3 had 141 patients (mean age 61 ± 8 years). The hfPWV and baPWV increased significantly along with the hsCRP level. Group 1, Group 2 and Group 3 demonstrated hfPWV and baPWV of 965 ± 199 and 1438 ± 246, 975 ± 174 and 1487 ± 258 and 1043 ± 215 and 1566 ± 252 cm/s, respectively (p < 0.01). The hfPWV also showed a strong correlation with baPWV (r = 0.698, p < 0.001). The hsCRP level was independently associated with arterial stiffness (hfPWV: R2 = 0.273, p < 0.001; baPWV: R2 = 0.284, p = 0.001) after controlling for age, body mass index, systolic blood pressure (BP), heart rate, gender, HDL-cholesterol, triglyceride, glucose level and medications. In conclusion, hsCRP was associated with arterial stiffness, independent of age, systolic BP, gender, heart rate, glucose, lipid profiles and medications in treated hypertension. Therefore, hsCRP could be a useful marker of arterial stiffness in treated hypertension patients and a possible target for arterial inflammation in hypertension.

Original languageEnglish
Pages (from-to)401-406
Number of pages6
JournalAtherosclerosis
Volume192
Issue number2
DOIs
Publication statusPublished - 2007 Jun 1

Fingerprint

Vascular Stiffness
C-Reactive Protein
Pulse Wave Analysis
Thigh
Ankle
Hypertension
Arm
Blood Pressure
Heart Rate
Glucose
Arteritis
HDL Cholesterol
Blood Vessels
Triglycerides
Body Mass Index
Inflammation
Lipids

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Kim, Jung Sun ; Kang, Tae Soo ; Kim, Jin Bae ; Seo, Hye Sun ; Park, Sungha ; Kim, Changsoo ; Ko, Young Guk ; Choi, Donghoon ; Jang, Yangsoo ; Chung, Namsik. / Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. In: Atherosclerosis. 2007 ; Vol. 192, No. 2. pp. 401-406.
@article{2d5f8e7022e7452bad1c2e11787fe183,
title = "Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients",
abstract = "C-reactive protein (CRP) has been known to be associated with vascular inflammation and hypertension. Pulse wave velocity (PWV) increases according to the degree of the arterial stiffness in hypertension patients. Therefore, PWV may be correlated with CRP levels in treated hypertensive patients, irrespective of medication. We sought to determine whether there is a correlation between hsCRP and arterial stiffness in non-diabetic treated hypertensive patients, independent of cardiovascular risk factor. This study consisted of 424 non-diabetic patients at least 45-years-old who were being treated for hypertension. At the time of enrollment, the patients underwent a baseline laboratory assessment of C-reactive protein levels and pulse wave velocity (PWV). Heart to femoral PWV (hfPWV) and brachial to ankle PWV (baPWV) were used as a marker of arterial stiffness. Subjects were categorized according to tertiles of hsCRP level [Group 1: first tertile (0.20-0.46 mg/L), Group 2: second tertile (0.47-1.15 mg/L), Group 3: third tertile (1.17-9.71 mg/L)]. Group 1 consisted of 141 patients (mean age 58 ± 8 years), Group 2 had 142 patients (mean age 60 ± 9 years) and Group 3 had 141 patients (mean age 61 ± 8 years). The hfPWV and baPWV increased significantly along with the hsCRP level. Group 1, Group 2 and Group 3 demonstrated hfPWV and baPWV of 965 ± 199 and 1438 ± 246, 975 ± 174 and 1487 ± 258 and 1043 ± 215 and 1566 ± 252 cm/s, respectively (p < 0.01). The hfPWV also showed a strong correlation with baPWV (r = 0.698, p < 0.001). The hsCRP level was independently associated with arterial stiffness (hfPWV: R2 = 0.273, p < 0.001; baPWV: R2 = 0.284, p = 0.001) after controlling for age, body mass index, systolic blood pressure (BP), heart rate, gender, HDL-cholesterol, triglyceride, glucose level and medications. In conclusion, hsCRP was associated with arterial stiffness, independent of age, systolic BP, gender, heart rate, glucose, lipid profiles and medications in treated hypertension. Therefore, hsCRP could be a useful marker of arterial stiffness in treated hypertension patients and a possible target for arterial inflammation in hypertension.",
author = "Kim, {Jung Sun} and Kang, {Tae Soo} and Kim, {Jin Bae} and Seo, {Hye Sun} and Sungha Park and Changsoo Kim and Ko, {Young Guk} and Donghoon Choi and Yangsoo Jang and Namsik Chung",
year = "2007",
month = "6",
day = "1",
doi = "10.1016/j.atherosclerosis.2006.05.025",
language = "English",
volume = "192",
pages = "401--406",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. / Kim, Jung Sun; Kang, Tae Soo; Kim, Jin Bae; Seo, Hye Sun; Park, Sungha; Kim, Changsoo; Ko, Young Guk; Choi, Donghoon; Jang, Yangsoo; Chung, Namsik.

In: Atherosclerosis, Vol. 192, No. 2, 01.06.2007, p. 401-406.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients

AU - Kim, Jung Sun

AU - Kang, Tae Soo

AU - Kim, Jin Bae

AU - Seo, Hye Sun

AU - Park, Sungha

AU - Kim, Changsoo

AU - Ko, Young Guk

AU - Choi, Donghoon

AU - Jang, Yangsoo

AU - Chung, Namsik

PY - 2007/6/1

Y1 - 2007/6/1

N2 - C-reactive protein (CRP) has been known to be associated with vascular inflammation and hypertension. Pulse wave velocity (PWV) increases according to the degree of the arterial stiffness in hypertension patients. Therefore, PWV may be correlated with CRP levels in treated hypertensive patients, irrespective of medication. We sought to determine whether there is a correlation between hsCRP and arterial stiffness in non-diabetic treated hypertensive patients, independent of cardiovascular risk factor. This study consisted of 424 non-diabetic patients at least 45-years-old who were being treated for hypertension. At the time of enrollment, the patients underwent a baseline laboratory assessment of C-reactive protein levels and pulse wave velocity (PWV). Heart to femoral PWV (hfPWV) and brachial to ankle PWV (baPWV) were used as a marker of arterial stiffness. Subjects were categorized according to tertiles of hsCRP level [Group 1: first tertile (0.20-0.46 mg/L), Group 2: second tertile (0.47-1.15 mg/L), Group 3: third tertile (1.17-9.71 mg/L)]. Group 1 consisted of 141 patients (mean age 58 ± 8 years), Group 2 had 142 patients (mean age 60 ± 9 years) and Group 3 had 141 patients (mean age 61 ± 8 years). The hfPWV and baPWV increased significantly along with the hsCRP level. Group 1, Group 2 and Group 3 demonstrated hfPWV and baPWV of 965 ± 199 and 1438 ± 246, 975 ± 174 and 1487 ± 258 and 1043 ± 215 and 1566 ± 252 cm/s, respectively (p < 0.01). The hfPWV also showed a strong correlation with baPWV (r = 0.698, p < 0.001). The hsCRP level was independently associated with arterial stiffness (hfPWV: R2 = 0.273, p < 0.001; baPWV: R2 = 0.284, p = 0.001) after controlling for age, body mass index, systolic blood pressure (BP), heart rate, gender, HDL-cholesterol, triglyceride, glucose level and medications. In conclusion, hsCRP was associated with arterial stiffness, independent of age, systolic BP, gender, heart rate, glucose, lipid profiles and medications in treated hypertension. Therefore, hsCRP could be a useful marker of arterial stiffness in treated hypertension patients and a possible target for arterial inflammation in hypertension.

AB - C-reactive protein (CRP) has been known to be associated with vascular inflammation and hypertension. Pulse wave velocity (PWV) increases according to the degree of the arterial stiffness in hypertension patients. Therefore, PWV may be correlated with CRP levels in treated hypertensive patients, irrespective of medication. We sought to determine whether there is a correlation between hsCRP and arterial stiffness in non-diabetic treated hypertensive patients, independent of cardiovascular risk factor. This study consisted of 424 non-diabetic patients at least 45-years-old who were being treated for hypertension. At the time of enrollment, the patients underwent a baseline laboratory assessment of C-reactive protein levels and pulse wave velocity (PWV). Heart to femoral PWV (hfPWV) and brachial to ankle PWV (baPWV) were used as a marker of arterial stiffness. Subjects were categorized according to tertiles of hsCRP level [Group 1: first tertile (0.20-0.46 mg/L), Group 2: second tertile (0.47-1.15 mg/L), Group 3: third tertile (1.17-9.71 mg/L)]. Group 1 consisted of 141 patients (mean age 58 ± 8 years), Group 2 had 142 patients (mean age 60 ± 9 years) and Group 3 had 141 patients (mean age 61 ± 8 years). The hfPWV and baPWV increased significantly along with the hsCRP level. Group 1, Group 2 and Group 3 demonstrated hfPWV and baPWV of 965 ± 199 and 1438 ± 246, 975 ± 174 and 1487 ± 258 and 1043 ± 215 and 1566 ± 252 cm/s, respectively (p < 0.01). The hfPWV also showed a strong correlation with baPWV (r = 0.698, p < 0.001). The hsCRP level was independently associated with arterial stiffness (hfPWV: R2 = 0.273, p < 0.001; baPWV: R2 = 0.284, p = 0.001) after controlling for age, body mass index, systolic blood pressure (BP), heart rate, gender, HDL-cholesterol, triglyceride, glucose level and medications. In conclusion, hsCRP was associated with arterial stiffness, independent of age, systolic BP, gender, heart rate, glucose, lipid profiles and medications in treated hypertension. Therefore, hsCRP could be a useful marker of arterial stiffness in treated hypertension patients and a possible target for arterial inflammation in hypertension.

UR - http://www.scopus.com/inward/record.url?scp=34248174340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248174340&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2006.05.025

DO - 10.1016/j.atherosclerosis.2006.05.025

M3 - Article

C2 - 16782104

AN - SCOPUS:34248174340

VL - 192

SP - 401

EP - 406

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -